Effect of Capecitabine on the Pharmacokinetics of BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Advanced Solid Tumors, Neoplasms
Both
Advanced Solid Tumors, Neoplasms
Trial Information
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
Inclusion Criteria:
- Recovery from surgery or radiation therapy
- Measurable or non-measurable disease
- Available for follow-up
Exclusion Criteria:
- Neuropathy
- Uncontrolled pulmonary or cardiovascular disease
- Known history of HIV infection
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Effect of capecitabine on the pharmacokinetics of BMS-247550 and to assess the effect of BMS-247550 on the pharmacokinetics of capecitabine
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA163-038
NCT ID:
NCT00207129
Start Date:
October 2004
Completion Date:
December 2005
Related Keywords:
- Advanced Solid Tumors
- Neoplasms
- Neoplasms
Name | Location |
|---|---|
| Local Institution | Austin, Texas |
